US › Healthcare

Polaryx Therapeutics, Inc. Common Stock (PLYX)

US · Healthcare · Biotechnology

$2.14+5.42%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-1.4M

EPS

$-0.03

EPS estimate

$-0.05

EPS came in at -0.03 against a street estimate of -0.05 — a beat of 40.0%.

Key statistics

Market cap

$99.2M

Forward P/E

0.0

P/B

9.48

Book value

$0.22

EPS (TTM)

$-0.13

52-week high

$48.91

52-week low

$1.85

50-day MA

$2.22

200-day MA

$4.06

Analyst view

with an average price target of $7.50.

Shareholding

Insiders

69.92%

Institutions

4.40%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.33%
Geode Capital Management, LLC	0.34%
Vanguard Fiduciary Trust Co	0.21%
State Street Corp	0.12%
BlackRock Inc	0.08%
Northern Trust Corp	0.06%
Bank of America Corp	0.05%
The Goldman Sachs Group Inc	0.03%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Polaryx Therapeutics, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.